

1 **Cohort profile: The Pregnancy, Arsenic, and Immune Response (PAIR) Study, a**  
2 **longitudinal pregnancy and birth cohort in rural northern Bangladesh**

3 Lindsay N. Avolio,<sup>1†</sup> Tyler J. S. Smith,<sup>1†</sup> Ana Navas-Acien,<sup>2</sup> Kate Kruczynski,<sup>1</sup> Nora Pisanic,<sup>1</sup>  
4 Pranay R. Randad,<sup>1</sup> Barbara Detrick,<sup>3</sup> Rebecca C. Fry,<sup>4</sup> Alexander van Geen,<sup>5</sup> Walter Goessler,<sup>6</sup>  
5 Ruth A. Karron,<sup>7</sup> Sabra L. Klein,<sup>8</sup> Elizabeth L. Ogburn,<sup>9</sup> Marsha Wills-Karp,<sup>1</sup> Kelsey Alland,<sup>7</sup> Kaniz  
6 Ayesha,<sup>10</sup> Brian Dyer,<sup>7</sup> Md. Tanvir Islam,<sup>10</sup> Habibat A. Oguntade,<sup>7,11</sup> Md. Hafizur Rahman,<sup>10</sup>  
7 Hasmat Ali,<sup>10</sup> Rezwanaul Haque,<sup>10</sup> Saijuddin Shaikh,<sup>10</sup> Kerry J. Schulze,<sup>7</sup> A. K. M.  
8 Muraduzzaman,<sup>12</sup> A. S. M. Alamgir,<sup>12</sup> Meerjady Sabrina Flora,<sup>12</sup> Keith P. West Jr.,<sup>7</sup> Alain B.  
9 Labrique,<sup>7</sup> Christopher D. Heaney,<sup>1,7,13\*</sup> for the JiVitA Maternal and Child Health and Nutrition  
10 Research Project

11

12 <sup>1</sup>Department of Environmental Health & Engineering, Johns Hopkins University, Baltimore, MD,  
13 USA

14 <sup>2</sup>Department of Environmental Health Sciences, Columbia University, New York, NY, USA

15 <sup>3</sup>Department of Pathology, Johns Hopkins University, Baltimore, MD, USA

16 <sup>4</sup>Department of Environmental Sciences & Engineering, University of North Carolina, Chapel Hill,  
17 NC, USA

18 <sup>5</sup>Lamont-Doherty Earth Observatory, Columbia University, Palisades, NY, USA

19 <sup>6</sup>Institute of Chemistry - Analytical Chemistry, University of Graz, Graz, Austria

20 <sup>7</sup>Department of International Health, Johns Hopkins University, Baltimore, MD, USA

21 <sup>8</sup>Department of Molecular Microbiology & Immunology, Johns Hopkins University, Baltimore, MD,  
22 USA

23 <sup>9</sup>Department of Biostatistics, Johns Hopkins University, Baltimore, MD, USA

24 <sup>10</sup>JiVitA Maternal and Child Health and Nutrition Research Project, Gaibandha, Bangladesh

25 <sup>11</sup>Division of Epidemiology and Community Health, University of Minnesota School of Public  
26 Health, Minneapolis, MN, USA

27 <sup>12</sup>Institute of Epidemiology, Disease Control, and Research, Dhaka, Bangladesh

28 <sup>13</sup>Department of Epidemiology, Johns Hopkins University, Baltimore, MD, USA

29

30 † LNA and TJSS contributed equally to this paper.

31

32 \* Corresponding Author:

33 Christopher D. Heaney, PhD, MS

34 Johns Hopkins Bloomberg School of Public Health

35 615 North Wolfe Street, Room 7033B

36 Baltimore, MD 21205

37 Phone: (443) 287-4989

38 E-mail: [cheaney1@jhu.edu](mailto:cheaney1@jhu.edu)

39

40 **ABSTRACT**

41 **Purpose:** Arsenic exposure and micronutrient deficiencies may alter immune reactivity to  
42 influenza vaccination in pregnant women, transplacental transfer of maternal antibodies to the  
43 fetus, and maternal and infant acute morbidity. The Pregnancy, Arsenic, and Immune Response  
44 (PAIR) Study is a longitudinal pregnancy and birth cohort designed to assess whether arsenic  
45 exposure and micronutrient deficiencies alter maternal or newborn immunity and acute morbidity  
46 following maternal seasonal influenza vaccination during pregnancy.

47 **Participants:** We enrolled 784 pregnant women in rural Gaibandha District in northern  
48 Bangladesh between October 2018 and March 2019. Women received a quadrivalent seasonal  
49 inactivated influenza vaccine at enrollment in the late first or early second trimester between 11  
50 and 17 weeks of gestational age. Follow-up included up to 13 visits between enrollment and three  
51 months postpartum as well as weekly telephone surveillance to ascertain influenza-like illness  
52 and other acute morbidity symptoms in women and infants. Tube well drinking water and urine  
53 specimens were collected to assess arsenic exposure. Of 784 women who enrolled, 736 (93.9%)  
54 delivered live births and 551 (70.3%) completed follow-up visit to three months postpartum.

55 **Findings to Date:** Arsenic was  $\geq 0.02$   $\mu\text{g/L}$  in 97.9% of water specimens collected from  
56 participants at enrollment. The medians (interquartile ranges) of water and urinary arsenic were  
57 5.1 (0.5-25.1)  $\mu\text{g/L}$  and 33.1 (19.6-56.5)  $\mu\text{g/L}$ , respectively. Water and urinary arsenic were  
58 strongly correlated (Spearman's  $\rho=0.72$ ) among women with water arsenic  $\geq$  median but weakly  
59 correlated ( $\rho=0.18$ ) among women with water arsenic  $<$  median.

60 **Future Plans:** The PAIR Study is well positioned to examine the effects of low-moderate arsenic  
61 exposure and micronutrient deficiencies on immune outcomes in women and infants.

62 **Registration:** NCT03930017

## 63 INTRODUCTION

64 Arsenic exposure is a major threat to global health. About 140 million people worldwide  
65 are exposed to drinking water arsenic exceeding the World Health Organization's (WHO's)  
66 guideline value of 10 µg/L [1]. Arsenic causes bladder, lung, and skin cancers [2] and has been  
67 associated with cardiovascular disease, diabetes mellitus, and the metabolic syndrome [3,4].  
68 Over the past decade, multiple studies have found that arsenic was associated with altered  
69 cellular [5] and humoral immune responses [6–8] and increased risk of infection, acute morbidity,  
70 and related mortality [9–12]. Of particular concern is immunotoxicity following exposure during  
71 pregnancy and early life [13]. However, while exposure *in utero* has been associated with reduced  
72 pathogen-specific antibody responses to some childhood vaccinations [6–8] and increased risk  
73 of respiratory and gastrointestinal morbidities in children [14–21], less is known about arsenic and  
74 the immune response in pregnant women and newborns during the first months of life. In addition,  
75 arsenic methylation facilitated by one-carbon metabolism appears to modify arsenic toxicity for  
76 certain chronic disease outcomes [22]. Arsenic methylation is known to shift during pregnancy  
77 [23,24]. However, few studies of arsenic immunotoxicity have evaluated potential effect measure  
78 modification by micronutrient deficiencies that influence arsenic methylation in pregnant women.

79 The WHO recommends seasonal influenza vaccination at any stage of pregnancy to  
80 protect pregnant women and infants <6 months of age [25], who benefit from maternal antibodies  
81 transferred across the placenta [26–28]. Since the risk of severe illness from infection by influenza  
82 virus is higher in pregnant women and infants [29,30], expanding maternal vaccination against  
83 influenza is imperative. If arsenic reduces the maternal antibody response to influenza vaccine or  
84 transplacental transfer of maternal antibodies to the fetus, however, additional interventions may  
85 be needed. Yet relations among arsenic exposure, micronutrient deficiencies, antibody responses  
86 to influenza vaccination in pregnant women, transplacental transfer of maternal antibodies, and  
87 influenza-like illness (ILI) and other acute morbidities remain understudied [31,32].

88 To better understand the influence of arsenic on immune responses in pregnant women  
89 and newborns, we established the Pregnancy, Arsenic, and Immune Response (PAIR) Study, a  
90 longitudinal pregnancy and birth cohort, in rural northern Bangladesh. The PAIR Study was  
91 designed to assess whether arsenic exposure and micronutrient deficiencies alter maternal or  
92 newborn immunity and acute morbidity following maternal seasonal influenza vaccination during  
93 pregnancy. We hypothesized that arsenic exposure and one-carbon metabolism micronutrient  
94 deficiencies may alter maternal and newborn influenza antibody titer and avidity, measures of  
95 systemic immune responses, and respiratory and other acute morbidity outcomes among  
96 pregnant women and newborns.

97

## 98 **COHORT DESCRIPTION**

### 99 **Study Area**

100 The PAIR Study is based at the JiVitA Maternal and Child Health and Nutrition Research  
101 Project (JiVitA) in rural northern Bangladesh. Approximately 45 million people in Bangladesh are  
102 exposed to arsenic concentrations in drinking water  $>10$   $\mu\text{g/L}$  (the WHO guideline value) and, of  
103 these, approximately 20 million people are exposed to arsenic concentrations  $>50$   $\mu\text{g/L}$  (the  
104 Bangladesh national standard) [33]. For nearly two decades, JiVitA has been one of the largest  
105 research project sites in South Asia, covering  $\sim 650,000$  people over  $450$   $\text{km}^2$  of Bangladesh's  
106 Gaibandha and Rangpur Districts (**Figure 1**) [34]. JiVitA is an extensive field organization that  
107 has conducted large trials of food and micronutrient supplements among pregnant women and  
108 children [35–37]. A case-control study nested in a previous JiVitA micronutrient supplement trial  
109 found that urinary arsenic was associated with seroconversion to hepatitis E virus between the  
110 first trimester and three months postpartum among pregnant women in the study area [9]. The  
111 PAIR Study builds on this work.

112

### 113 **Enrollment and Vaccination**

114 From July 2018 to February 2019, we conducted pregnancy surveillance to identify eligible  
115 pregnant women in the study area. A married woman of reproductive age (13-45 years) was  
116 eligible for the PAIR Study if she was pregnant and 13-14 weeks of gestational age (GW) (later  
117 13-16 GW; see below), had no pre-existing immunodeficiency or chronic infection, had no  
118 previous or current use of immune-altering drugs or therapies (e.g., steroids), and had not yet  
119 received an influenza vaccine for the 2018-19 influenza season.

120 The full JiVitA study area is divided into 566 sectors of ~150-300 households each (**Figure**  
121 **1**). For the PAIR Study, surveillance began in 175 sectors closest to clinical centers where  
122 vaccination and biospecimen collections, including venipuncture, could be safely performed and  
123 samples could be uniformly processed (“PAIR Original Area” in **Figure 1**). We estimated *a priori*  
124 that enrolling 850 pregnant women in 13-14 GW would yield a target sample size of 400 mother-  
125 infant pairs retained in the study to three months postpartum. We also determined *a priori* that  
126 enrollment should end by March 2019 so that pregnancies would be limited to a single influenza  
127 season and follow-up visits at 28 days post-vaccination would occur before the Ramadan fast  
128 (May 5 to June 3, 2019). In November 2018, seeking to achieve the target enrollment in this time  
129 window, we enlarged the study area by 163 sectors (“PAIR Extension Areas” in **Figure 1**) and  
130 expanded eligibility criteria to 13-16 GW.

131 A total of 66,055 married women of reproductive age living in the original or extension  
132 areas were identified by an earlier census or during pregnancy surveillance (**Figure 2**). During  
133 surveillance, a female community health research worker (CHRW) visited each household every  
134 four weeks and asked each married woman of reproductive age about the date of her last  
135 menstrual period. If the date was >30 days prior to the visit, the woman was offered a urine  
136 pregnancy test. A positive test indicated that the woman was pregnant. Gestational age was  
137 calculated from the date of her last menstrual period. We completed at least one surveillance visit  
138 to 46,775 women to identify 2,615 pregnant women (**Figure 2**). Of these, 845 women were eligible  
139 and consented to enrollment, and 784 women enrolled in the PAIR Study between October 2018

140 and March 2019 (**Figure 2**). At enrollment, women received a quadrivalent seasonal inactivated  
141 influenza vaccine (VaxigripTetra, Sanofi Pasteur, Lyon, France), which was recommended by the  
142 WHO for the 2018-19 Northern Hemisphere influenza season. We enrolled and administered the  
143 vaccine to 8 women in GW 11-12, 775 women in GW 13-16, and 1 woman in GW 17. All vaccines  
144 were maintained under a cold-chain protocol, carefully temperature-monitored, and administered  
145 by trained nurses working under the supervision of a JiVitA physician. The vaccine contained four  
146 inactivated influenza virus strains: A/Michigan/2015 (H1N1), A/Singapore/2016 (H3N2),  
147 B/Maryland/2016, and B/Phuket/2013 [38].

148 Sociodemographic characteristics, including age, education, socioeconomic status,  
149 household size (number of people), and house size (number of rooms excluding the kitchen and  
150 storerooms), were similar between pregnant women who enrolled (n=784) and pregnant women  
151 who did not enroll in the PAIR Study (n=1,519, after excluding women who were missing  
152 sociodemographic information [n=313]) (**Table 1**). Women who enrolled tended to be younger  
153 and have higher socioeconomic status, but the differences were small (**Table 1**). Socioeconomic  
154 status was assessed by living standards index, which was generated by a principal components  
155 analysis of household assets and home construction materials and validated in a previous JiVitA  
156 study [39]. The use of tube wells to obtain groundwater for drinking and cooking was nearly  
157 universal among enrollees (99.4%) and non-enrollees (99.8%) alike (**Table 1**).

158 **Table 1. Sociodemographic characteristics [n (%)] of pregnant women in the study area by**  
 159 **enrollment in the Pregnancy, Arsenic, and Immune Response (PAIR) Study, Gaibandha**  
 160 **District, Bangladesh, 2018-2019.**

	<b>Enrolled</b> (n=784)	<b>Not Enrolled*</b> (n=1,519)	<i>p</i>
<b>Age (years)**</b>			
<20	89 (11.4)	175 (11.5)	<i>&lt;0.01</i>
20 to 29	499 (63.6)	859 (56.6)	
≥30	194 (24.7)	479 (31.5)	
Missing	2 (0.3)	6 (0.4)	
<b>Maternal Education</b>			
None	92 (11.7)	212 (14.0)	<i>0.14</i>
Class 1 to 9	548 (69.9)	1,065 (70.1)	
Class ≥10	144 (18.4)	240 (15.8)	
Missing	0 (0)	2 (0.1)	
<b>Living Standards Index</b>			
<Median	360 (45.9)	792 (52.1)	<i>&lt;0.01</i>
≥Median	424 (54.1)	727 (47.9)	
<b>Household Size (people)</b>			
2 to 3	307 (39.2)	518 (34.1)	<i>0.05</i>
4 to 5	336 (42.9)	720 (47.4%)	
≥6	139 (17.7)	277 (18.2)	
Missing	2 (0.3)	4 (0.3)	
<b>House Size (rooms)***</b>			
0 to 1	366 (46.7)	721 (47.5)	<i>0.93</i>
2 to 3	367 (46.8)	699 (46.0)	
≥4	51 (6.5)	98 (6.5)	
Missing	0 (0)	1 (0.1)	
<b>Drinking Water Source</b>			
Tube Well	779 (99.4)	1,516 (99.8)	-
Other	5 (0.6)	3 (0.2)	

161  
 162 *Notes: All p values were calculated using  $\chi^2$  tests. A p value for Drinking Water Source was*  
 163 *omitted because the number of people in the “Other” category was too small. \*The table does not*  
 164 *include non-enrolled women who did not complete a separate visit to assess sociodemographic*  
 165 *variables (n=313). \*\*Age as of July 2018 (start of pregnancy surveillance). \*\*\*Number of rooms*  
 166 *excluding kitchen and storerooms.*



167 **Follow-up**

168 Study Visits

169 *In-person Visits*

170 We completed up to 13 in-person visits to implement questionnaires and collect biological and  
171 environmental specimens, beginning at enrollment and continuing to three months postpartum,  
172 for a follow-up period of roughly 10-11 months, depending on the timing and duration of each  
173 pregnancy (**Tables 2 and 3**). These included up to eight visits to the woman during pregnancy  
174 and up to five visits to mother-infant pairs after live birth. At three visits (enrollment and  
175 vaccination, 28 days post-vaccination, and three months postpartum), the CHRW brought  
176 participants (the mother in pregnancy, the mother-infant pair after live birth) to a local clinical  
177 center for detailed questionnaire and biospecimen collection. To minimize burden on mothers and  
178 infants in the neonatal period, two home visits were conducted shortly after any live birth and  
179 again within the first month postpartum for further questionnaire and biospecimen collection. Of  
180 784 women who enrolled, 744 (94.9%) completed the 28-day post-vaccination visit, 598 (76.3%)  
181 completed a visit within the first month postpartum, and 551 (70.3%) completed the three-month  
182 postpartum visit (**Table 4**). In total, 736 (93.9%) enrolled women had 750 live births. Age,  
183 gestational age, parity, education, living standards index, household size (number of people),  
184 house size (number of rooms), height (cm), body mass index (kg/m<sup>2</sup>), and urinary arsenic were  
185 similar among the women who enrolled and the subset of women who completed follow-up at  
186 three months postpartum (**Table 4**).

187

188 *Weekly Telephone Surveillance*

189 In partnership with the Institute of Epidemiology Disease Control and Research (IEDCR), a unit  
190 of the Bangladesh Ministry of Health and Family Welfare, we conducted weekly telephone  
191 surveillance to ascertain acute morbidities in women (enrollment to three months postpartum) and  
192 infants (birth to three months of age). In women, we ascertained high fever with cough, high fever

193 with sore throat, diarrhea, vomiting, and abdominal pain. If a woman reported high fever with  
194 cough or sore throat, she was asked further if she had congestion, headache, or chills at the same  
195 time. In infants, we ascertained high fever with cough, diarrhea, and vomiting. If a woman reported  
196 that her infant had high fever with cough, she was asked further if the infant had congestion or  
197 shortness of breath at the same time. Of 784 women enrolled in the PAIR Study and 750 infants  
198 born to them, 743 women (94.8%) and 628 infants (83.7%) participated in the surveillance. While  
199 weekly telephone surveillance was prespecified to end at three months postpartum, for some  
200 women and infants it continued for longer. The median (interquartile range [IQR]) number of  
201 weeks with complete calls was 35 (23-42) for women and 17 (12-22) for infants.

202

### 203 Environmental Specimens

204 We collected a water specimen from the tube well that each participant indicated was her primary  
205 source of drinking water before each center visit and at the home visit conducted within one month  
206 postpartum (**Table 2**). Just prior to collection, the well was flushed for approximately five minutes.  
207 Specimens were collected into conical vials certified by the manufacturer as trace-metal free (<1  
208 µg/L for 20 metals, including As), and transported to the local JiVitA lab at 4-10°C. Specimens  
209 were aliquoted and stored at -20°C prior to analysis. Tube well water specimens were analyzed  
210 for total arsenic (wAs) and other elements (Al, Ba, Br, Ca, Cd, Cu, Fe, K, Mg, Mn, Mo, Na, P, Pb,  
211 S, Sb, Si, Sr, U, V, W, Zn) at the Lamont-Doherty Earth Observatory in Palisades, NY using  
212 inductively coupled plasma mass spectrometry [40]. Empty trace metal-free conical vials and  
213 aliquot tubes were assessed as blanks. The LOD for wAs was 0.02 µg/L.

214

### 215 Biological Specimens

216 Up to 22 mL of venous blood was collected from mothers at each of the three center visits:  
217 enrollment/vaccination, 28 days post-vaccination, and three months postpartum (**Table 2**). Up to  
218 1 mL of capillary blood was collected from infants by heel stick during the center visit at three

219 months postpartum (**Table 3**). At the home visit within approximately one month of live birth, blood  
220 was collected from mothers and infants using the methods described for the center visits. Blood  
221 specimens were transported in temperature-controlled and -monitored coolers to a JiVitA  
222 laboratory. Laboratory technicians processed maternal blood to serum, plasma, and peripheral  
223 blood mononuclear cells (PBMCs), and processed infant blood to serum, on the day of collection.  
224 Serum and plasma were frozen and maintained at -80°C. PBMCs were cryopreserved following  
225 established protocols [41]. Serum and plasma were shipped on dry ice, and PBMCs were shipped  
226 in vapor phase liquid nitrogen canisters, to the Johns Hopkins University in Baltimore, Maryland.  
227 Maternal and infant sera were tested for antibody for the influenza vaccine antigens by  
228 hemagglutination-inhibition (HAI) assay at Sanofi Pasteur in Swiftwater, Pennsylvania [42]. We  
229 also will determine avidity of IgG antibodies specific to the influenza vaccine antigens; serum  
230 cytokine and chemokine concentrations as measures of immune function; immune cell population  
231 characterization; and T-cell stimulation assays using the influenza vaccine antigens.  
232 Micronutrients relevant to one-carbon metabolism will be measured in maternal plasma.

233 Urine was collected from all mothers at the three center visits and during the home visit  
234 within one month of birth, and from a subset of mothers (n=468) during a home visit in late  
235 pregnancy (**Table 2**). Mothers were asked to provide a urine specimen in a collection cup. A  
236 CHRW immediately transferred the specimen to a container certified by the manufacturer as  
237 trace-metal free (<1 µg/L for 20 metals, including As) and the specimens were transported to the  
238 JiVitA laboratory. Urine specimens were aliquoted and stored at -20°C prior to analysis. Urinary  
239 elements (Al, Ba, Br, Ca, Cd, Cs, Cu, Fe, K, Li, Mg, Mn, Mo, Na, P, Pb, Rb, S, Sb, Se, Si, Sr, U,  
240 V, W, Zn) were measured at the Institute of Chemistry - Analytical Chemistry at the University of  
241 Graz in Graz, Austria using inductively coupled plasma tandem mass spectrometry (ICP-MS/MS).  
242 Urinary arsenic was speciated (arsenite, arsenate, monomethylarsonic acid (MMA),  
243 dimethylarsinic acid (DMA), and arsenobetaine and other cations) by high performance liquid  
244 chromatography (HPLC) with ICP-MS/MS as described by Scheer et al. [43]. Empty trace-metal

245 free containers and aliquot tubes were assessed as blanks. The limits of detection (LODs) for  
246 arsenic species were 0.05 µg/L. To assess arsenic exposure, we summed urinary inorganic  
247 arsenic (the sum of arsenite and arsenate; iAs), MMA, and DMA ( $\sum uAs$ ) [44]. To assess arsenic  
248 metabolism, we calculated proportions of urinary iAs, MMA, and DMA, relative to  $\sum uAs$ , and  
249 reported them as iAs%, MMA%, and DMA% [22]. All urinary concentrations were corrected for  
250 specific gravity measured by refractometric determination of total solids.

251 We collected oral fluid, which includes saliva, oral mucosal transudate from the capillary  
252 bed, and crevicular fluid, from mothers at each center visit, the home visit after birth, and additional  
253 monthly home visits, and from infants in all visits beginning at one month postpartum (**Tables 2**  
254 **and 3**). Crevicular fluid, which flows between the gums and the teeth, is rich in antibodies and  
255 reflects the IgG profile of the serum. Oral fluid was collected by brushing the gum line with an  
256 oral-mucosal transudate collection swab [45–47]. Microsphere magnetic bead-based assays will  
257 be applied to measure IgG and IgA responses specific to the influenza vaccine strains as well as  
258 a variety of endemic respiratory and gastrointestinal pathogens [45,46,48].

259 If a mother reported influenza-like illness (ILI) in herself or her infant during weekly  
260 surveillance, a CHRW aimed to conduct a home visit and collect a nasal swab within 24 hours of  
261 the call (**Tables 2 and 3**). ILI was defined as high fever with cough or sore throat in women and  
262 high fever with cough in infants [49]. Severity was determined by calculating the sum of acute  
263 morbidity symptoms reported during surveillance. Given limited capacity, women or infants with  
264 the highest sum score were prioritized for the collection of a nasal swab. After collection by a  
265 CHRW, swabs were placed in universal transport medium. The transport medium was intended  
266 for the preservation of viruses (Puritan UniTranz-RT, Guilford, ME, USA). Samples were  
267 transported to the local JiVitA lab and stored at -80°C. Nasal swabs were periodically batch-  
268 transported to IEDCR in Dhaka, Bangladesh, in liquid nitrogen, where RNA will be extracted and  
269 tested by RT-qPCR for influenza A and B virus, including sub-types, according to WHO protocols  
270 to assess laboratory-confirmed ILI [50].

271

## 272 Anthropometry

273 Maternal weight (kg), height (cm), mid-upper arm circumference (MUAC) (cm), and triceps and  
274 subscapular skinfolds (mm) were measured at enrollment/vaccination and three months  
275 postpartum (**Table 2**) [36,43,52]. Maternal weight was also measured at 28 days post-vaccination,  
276 late pregnancy, and one-month postpartum. Maternal MUAC was also measured at late  
277 pregnancy and one-month postpartum. Infant weight, MUAC, chest circumference, head  
278 circumference, and length were recorded at the birth assessment visit (**Table 3**) [36,43,52]. Infant  
279 growth was monitored by repeating these measurements at one- and three-months postpartum.

280

## 281 Vitals

282 Blood pressure, hemoglobin, and body temperature of mothers were measured by a local nurse  
283 each time a mother had blood drawn (**Table 2**). Systolic and diastolic blood pressure were  
284 measured twice, in the left arm, with the woman in a relaxed and seated position using a  
285 WelchAllyn DuraShock DS66 Trigger Aneroid Sphygmomanometer (Skaneateles Falls, New  
286 York, USA). Hemoglobin was measured in capillary blood by real-time assay using a HemoCue  
287 Hb 301 analyzer (Ängelholm, Sweden). Body temperature of infants was measured at the birth  
288 assessment and three months postpartum, and hemoglobin was measured at three months  
289 postpartum by a local nurse (**Table 3**). Vitals were recorded and provided to the mother after each  
290 collection. Pregnant women and infants who were severely anemic (hemoglobin <7 g/dL)[53]  
291 were given iron tablets and iron syrup, respectively, consistent with the study protocol and as  
292 approved by the IRB. Blood type was determined using anti-A, anti-B, and anti-D blood grouping  
293 reagents (Cromatest, LiNEAR, Montgat, Spain).

294

## 295 Questionnaires

296 Questionnaires conducted at multiple visits between enrollment/vaccination and three months  
297 postpartum covered a variety of topics (**Table 2**), including questions related to the intentionality  
298 of pregnancy, seven- and thirty-day morbidity including influenza-like illness, seven-day food  
299 frequency, mental health, seven-day strenuous work activity, six-month pesticide storage and  
300 use, poultry farming and exposures, handwashing practices, tobacco use and smoke exposure,  
301 medical and vaccination history, household food security, and more. Additional questionnaires  
302 asked about the birth and delivery of infants, including characteristics of labor and delivery,  
303 micronutrient supplement consumption, and health crisis events. Answers to questionnaires for  
304 infants were most often provided by the mother, and included morbidity, breastfeeding practices,  
305 early feeding practices, infant injury and bleeding, immunization and supplementation, and  
306 hospitalization history and medication use (**Table 3**). Topics related to arsenic exposure included  
307 drinking water, rice products, and tobacco products and smoke exposure in the previous week.

308

### 309 **Patient and Public Involvement**

310 JiVitA was established and operates in consultation with local community stakeholders, many of  
311 whom are hired as JiVitA staff. JiVitA has benefited from their continued support for nearly two  
312 decades. Participants were not directly involved in the design of the PAIR Study.



Handwashing and latrine use	X									X
Tobacco use and exposure	X			X						X
Medical history	X									
Vaccination history	X									
Household food security	X									X
Tube well usage	X	X								X
Altered food consumption				X						
Planned location of delivery				X						
Date and time of birth						X				
Labor and delivery						X				
Micronutrient supplements								X		
Health crisis events								X		
Resumption of menstruation										X
Vaccination since enrollment										X

315

316 *Notes: Visit 0 = enrollment/vaccination, Visit 1 = 28 days post-vaccination, Visit 8 = birth assessment, Visit 9 = first month of life, Visit*  
317 *12 = three months post-partum, PBMCs = peripheral blood mononuclear cells. \* Timing of visit varied depending on pregnancy timing*  
318 *and duration. \*\* Urine collected in a subset of women. \*\*\* A nasal swab was collected if symptoms defining influenza-like illness were*  
319 *reported during weekly telephone surveillance, based on severity.*



320 **Table 3. Measurements collected in infants in the Pregnancy, Arsenic, and Immune**  
 321 **Response (PAIR) Study, Gaibandha District, Bangladesh, 2018-2019.**

Visit	Postpartum					Both
	8	9	10	11	12	
<b>Biological Samples</b>						
Serum		X			X	
Oral fluid			X	X	X	
Nasal swab						X*
<b>Anthropometry</b>						
Weight	X		X		X	
Length	X		X		X	
Mid-upper arm circumference	X		X		X	
Chest circumference	X		X		X	
Head circumference	X		X		X	
<b>Vitals</b>						
Body temperature		X			X	
Hemoglobin					X	
Blood typing					X	
<b>Questionnaires</b>						
Date and time of birth	X					
Birth outcome	X					
Condition of infant at birth	X					
Newborn care practices	X					
7-day morbidity		X	X	X	X	X
Morbidities in first 28 days			X			
Breastfeeding practices			X		X	
Early feeding			X			
Injury and bleeding			X			
Two-month morbidity	X					
Child's diet	X					
Immunization history					X	
Vitamin A supplementation					X	
Bleeding disorders					X	
Hospitalization history					X	
Recent medication					X	

322

323 *Notes: Visit 8 = birth assessment, Visit 9 = first month of life, Visit 12 = three months post-partum.*

324 *\* A nasal swab was collected if symptoms defining influenza-like illness were reported during*

325 *weekly telephone surveillance, based on severity.*

326 **Table 4. Sociodemographic characteristics [n (%)] of pregnant women at enrollment in the**  
 327 **Pregnancy, Arsenic, and Immune Response (PAIR) Study, Gaibandha District,**  
 328 **Bangladesh, 2018-2019, by completion of major study visits.**

	<b>Enrollment</b>	<b>28 Days Post-vaccination</b>	<b>First Month of Life</b>	<b>Three Months Post-partum</b>
Completed	784 (100)	744 (94.9)	598 (76.3)	551 (70.3)
<b>Maternal Age (years)*</b>				
<20	77 (9.8)	73 (9.8)	61 (10.2)	53 (9.6)
20 to 29	488 (62.2)	464 (62.4)	375 (62.7)	345 (62.6)
≥30	217 (27.7)	205 (27.6)	160 (26.8)	151 (27.4)
Missing	2 (0.3)	2 (0.3)	2 (0.3)	2 (0.4)
<b>Gestational Age (weeks)</b>				
11 to 13	306 (39.0)	284 (38.2)	227 (38.0)	204 (37.0)
14	250 (31.9)	242 (32.5)	198 (33.1)	186 (33.8)
15	104 (13.3)	101 (13.6)	80 (13.4)	73 (13.2)
16 to 17	124 (15.8)	117 (15.7)	93 (15.6)	88 (16.0)
<b>Parity</b>				
Nulliparous	140 (17.9)	136 (18.3)	107 (17.9)	90 (16.3)
Primiparous	364 (46.4)	340 (45.7)	278 (46.5)	262 (47.6)
Multiparous	280 (35.7)	268 (36.0)	213 (35.6)	199 (36.1)
<b>Maternal Education</b>				
None	92 (11.7)	89 (12.0)	60 (10.0)	57 (10.3)
Class 1 to 9	548 (69.9)	521 (70.0)	431 (72.1)	396 (71.9)
Class ≥10	144 (18.4)	134 (18.0)	107 (17.9)	98 (17.8)
<b>Living Standards Index</b>				
<Median	392 (50.0)	370 (49.7)	294 (49.2)	272 (49.4)
≥Median	392 (50.0)	374 (50.3)	304 (50.8)	279 (50.6)
<b>Household Size (people)</b>				
2 to 3	307 (39.2)	289 (38.8)	224 (37.5)	207 (37.6)
4 to 5	336 (42.9)	321 (43.1)	259 (43.3)	238 (43.2)
≥6	139 (17.7)	132 (17.7)	113 (18.9)	104 (18.9)
Missing	2 (0.3)	2 (0.3)	2 (0.3)	2 (0.4)
<b>House Size (rooms)</b>				
0 to 1	366 (46.7)	342 (46.0)	268 (44.8)	248 (45.0)
2 to 3	367 (46.8)	353 (47.4)	294 (49.2)	270 (49.0)
≥4	51 (6.5)	49 (6.6)	36 (6.0)	33 (6.0)
<b>Height (cm)</b>				
Mean (SD)	150 (5.20)	150 (5.19)	150 (5.17)	150 (5.19)
<b>Body Mass Index (kg/m<sup>2</sup>)</b>				
Mean (SD)	21.9 (3.44)	22.0 (3.41)	21.9 (3.36)	22.0 (3.36)
<b>Urine Arsenic (<math>\sum</math>uAs) (<math>\mu</math>g/L)**</b>				
Tertile 1 (2.98 to 22.5)	261 (33.3)	250 (33.6)	203 (33.9)	189 (34.3)
Tertile 2 (22.5 to 45.6)	261 (33.3)	248 (33.3)	193 (32.3)	175 (31.8)
Tertile 3 (46.3 to 451)	261 (33.3)	245 (32.9)	201 (33.6)	186 (33.8)
Missing	1 (0.1)	1 (0.1)	1 (0.2)	1 (0.2)

329 \* Age at enrollment. \*\* Urinary arsenic is the sum of inorganic and methylated arsenic species.

330

### 331 FINDINGS TO DATE

332 Water arsenic was  $\geq 0.02$   $\mu\text{g/L}$  in 97.9% of drinking water specimens collected from participants' tube wells on the day of enrollment. The median (IQR) of wAs was 5.1 (0.5-25.1)  $\mu\text{g/L}$  (**Figure 3**) with 39.4% of samples above the WHO guideline value of 10  $\mu\text{g/L}$  and 13.2% above the Bangladesh national standard of 50  $\mu\text{g/L}$ . wAs appears to be lower in the study area than in other regions of Bangladesh where epidemiologic studies have been conducted [54,55]. Urinary iAs, MMA, and DMA were  $\geq \text{LOD}$  in all specimens collected at enrollment. The median (IQR) of their sum,  $\sum \text{uAs}$ , was 33.1 (19.6-56.5)  $\mu\text{g/L}$  (**Figure 3**). Urinary arsenobetaine (and other unretained arsenic species) levels were low (median: 0.8  $\mu\text{g/L}$ , IQR: 0.4-1.7  $\mu\text{g/L}$ ), suggesting low exposure to organic arsenic from seafood in the population [56].  $\sum \text{uAs}$  was strongly correlated with wAs in participants with wAs  $\geq$  median (Spearman's  $\rho=0.72$ ) but weakly correlated with wAs in participants with wAs  $<$  median (Spearman's  $\rho=0.18$ ) (**Figure 4**). This suggests that, at lower concentrations of wAs, other sources of arsenic (e.g., other tube wells, rice) contribute relatively more to exposure [57].  $\sum \text{uAs}$  and wAs will provide complementary approaches to exposure assessment.  $\sum \text{uAs}$  integrates exposures from multiple sources, including drinking water and diet, but has a short biological half-life and may over- or under-estimate long-term exposure [44]. By contrast, wAs reflects a single source of exposure but is more stable over time. Future work will characterize exposure to arsenic and other metals and associations with health outcomes, including maternal antibody response to influenza vaccination, transplacental transfer of maternal antibodies, and respiratory morbidity, as well as interactions between arsenic exposure and micronutrient deficiencies in these outcomes.

352

### 353 STRENGTHS AND LIMITATIONS

354 Strengths of the PAIR Study include a large, representative sample of pregnant women and  
355 infants in rural northern Bangladesh. The women received the same seasonal influenza vaccine  
356 at approximately the same time during pregnancy and during the same influenza season. This  
357 design will enable us to assess whether arsenic exposure is associated with antibody responses  
358 to seasonal influenza vaccination in pregnant women or transplacental transfer of maternal  
359 antibodies to the fetus while avoiding potential confounders related to stage of pregnancy and  
360 annual variability in influenza viruses. Because wAs appears to be lower in the PAIR Study than  
361 in other epidemiologic studies in Bangladesh, we can assess whether low-moderate arsenic  
362 exposure is associated with relevant maternal and infant outcomes. Biological and environmental  
363 specimens provide objective measures of arsenic exposure and immune and respiratory and  
364 other acute morbidity outcomes. Weekly telephone surveillance provides ascertainment of ILI  
365 symptoms and real-time PCR testing of ILI-symptomatic event anterior nasal swabs provides  
366 time-resolved information on maternal and infant laboratory-confirmed influenza A/B infection.  
367 Limitations include occasional delays in study visits. While JiVitA possesses an extensive field  
368 organization, logistical barriers to conducting frequent home visits over a large study area  
369 prevented some study visits from occurring as scheduled. Additionally, it was not logistically  
370 feasible to collect umbilical cord blood specimens to assess transplacental transfer of maternal  
371 antibodies. However, infant-to-maternal HAI antibody titer ratios measured in serum during the  
372 first month of life should provide a reasonable alternative because neonates demonstrate only a  
373 limited adaptive immune response that would allow them to generate IgG antibodies  
374 independently [58], and the maternal antibodies received through breastfeeding are IgA.

375

## 376 **COLLABORATION**

377 The PAIR Study was designed and conducted through collaboration among investigators at the  
378 Johns Hopkins University, Columbia University, and the University of North Carolina at Chapel  
379 Hill in the United States; the University of Graz in Austria; and the JiVitA Maternal and Child Health

380 and Nutrition Research Project in Bangladesh. We welcome further collaboration. Please contact  
381 the principal investigators, Dr. Christopher D. Heaney [cheaney1@jhu.edu] and Dr. Alain B.  
382 Labrique [alabriq1@jhu.edu], for more information.

383 **FURTHER DETAILS**

384 Contributions

385 LNA and TJSS contributed equally to this paper. **LNA:** Writing – Original Draft, Data Curation,  
386 Methodology, Visualization; **TJSS:** Writing – Original Draft, Data Curation, Formal Analysis,  
387 Software, Visualization; **ANA:** Writing – Review & Editing, Conceptualization, Methodology,  
388 Supervision; **KK:** Data Curation, Resources; **NP:** Writing – Review & Editing, Conceptualization,  
389 Data Curation, Methodology, Project Administration; **PRR:** Methodology, Project Administration;  
390 **B Detrick:** Writing – Review & Editing, Conceptualization, Methodology; **RCF:** Writing – Review  
391 & Editing, Conceptualization, Methodology; **AvG:** Writing – Review & Editing, Investigation,  
392 Methodology; **WG:** Writing – Review & Editing, Investigation, Methodology; **RAK:** Writing –  
393 Review & Editing, Conceptualization, Methodology; **SLK:** Writing – Review & Editing,  
394 Conceptualization, Methodology; **ELO:** Methodology; **MWK:** Conceptualization, Methodology,  
395 Resources; **K Alland:** Writing – Review & Editing, Conceptualization, Methodology, Supervision;  
396 **K Ayesha:** Investigation, Supervision; **B Dyer:** Data Curation, Software; **MTI:** Investigation,  
397 Methodology; **HAO:** Investigation, Project Administration; **MHR:** Investigation, Methodology,  
398 Supervision; **HA:** Investigation, Methodology, Project Administration, Supervision; **RH:** Data  
399 Curation, Methodology, Supervision; **SS:** Conceptualization, Methodology, Project  
400 Administration, Supervision; **KJS:** Writing – Review & Editing, Conceptualization; **AKMM:**  
401 Investigation, Methodology; **ASMA:** Conceptualization, Methodology, Supervision; **MSF:**  
402 Methodology, Supervision; **KPW:** Conceptualization, Funding Acquisition, Supervision; **ABL:**  
403 Conceptualization, Funding Acquisition, Investigation, Methodology, Project Administration,  
404 Supervision; **CDH:** Writing – Review & Editing, Conceptualization, Data Curation, Funding  
405 Acquisition, Investigation, Methodology, Project Administration, Resources, Supervision.

406

407 Funding

408 The PAIR study was supported by the National Institute of Environmental Health Sciences  
409 (NIEHS; R01ES026973) and by an unrestricted grant from Sanofi Pasteur, Lyon, France, which  
410 also provided the study vaccine and vaccine antibody testing. PAIR also benefited from common  
411 JiVitA infrastructure and staff supported by the UBS Optimus Foundation and the Bill & Melinda  
412 Gates Foundation. LNA was supported by a grant from the U.S. Centers for Disease Control and  
413 Prevention, National Institute for Occupational Safety and Health to the Johns Hopkins Education  
414 and Research Center for Occupational Safety and Health (T42 OH0008428) and the National  
415 Science Foundation Graduate Research Fellowship (DGE-1746891). TJSS was supported by  
416 NIEHS (T32ES007141).

417

#### 418 Competing Interests

419 The authors declare they have no competing interests.

420

#### 421 Ethics Approval

422 This study was approved by the institutional review boards of the Johns Hopkins Bloomberg  
423 School of Public Health (00008247) and the Institute of Epidemiology, Disease Control and  
424 Research (IEDCR/IRB/2017/07). All participants gave informed consent prior to enrollment.

425 **REFERENCES**

- 426 1 Ravenscroft P, Brammer H, Richards K. *Arsenic Pollution: A Global Synthesis*. West  
427 Sussex: Wiley-Blackwell 2009. doi:10.1002/9781444308785
- 428 2 International Agency for Research on Cancer (IARC). *Arsenic and Arsenic Compounds*.  
429 Geneva: World Health Organization 2012.
- 430 3 Moon KA, Oberoi S, Barchowsky A, *et al*. A dose-response meta-analysis of chronic  
431 arsenic exposure and incident cardiovascular disease. *Int J Epidemiol* 2017;**46**:1924–39.  
432 doi:10.1093/ije/dyx202
- 433 4 Navas-Acien A, Sprattlen MJ, Abuawad A, *et al*. Early-Life Arsenic Exposure, Nutritional  
434 Status, and Adult Diabetes Risk. *Curr Diab Rep* 2019;**19**:147–54. doi:10.1007/s11892-019-  
435 1272-9
- 436 5 Ahmed S, Moore SE, Kippler M, *et al*. Arsenic exposure and cell-mediated immunity in pre-  
437 school children in rural Bangladesh. *Toxicol Sci* 2014;**141**:166–75.  
438 doi:10.1093/toxsci/kfu113
- 439 6 Welch BM, Branscum A, Geldhof GJ, *et al*. Evaluating the effects between metal mixtures  
440 and serum vaccine antibody concentrations in children: A prospective birth cohort study.  
441 *Environ Health* 2020;**19**:41. doi:10.1186/s12940-020-00592-z
- 442 7 Welch BM, Branscum A, Ahmed SM, *et al*. Arsenic exposure and serum antibody  
443 concentrations to diphtheria and tetanus toxoid in children at age 5: A prospective birth  
444 cohort in Bangladesh. *Environ Int* 2019;**127**:810–8. doi:10.1016/j.envint.2019.04.015
- 445 8 Raqib R, Ahmed S, Ahsan K bin, *et al*. Humoral immunity in arsenic-exposed children in  
446 rural Bangladesh: Total immunoglobulins and vaccine-specific antibodies. *Environ Health*  
447 *Perspect* 2017;**125**:067006. doi:10.1289/EHP318
- 448 9 Heaney CD, Kmush B, Navas-Acien A, *et al*. Arsenic exposure and hepatitis E virus  
449 infection during pregnancy. *Environ Res* 2015;**142**:273–80.  
450 doi:10.1016/j.envres.2015.07.004



- 451 10 Kile ML, Rodrigues EG, Mazumdar M, *et al.* A prospective cohort study of the association  
452 between drinking water arsenic exposure and self-reported maternal health symptoms  
453 during pregnancy in Bangladesh. *Environ Health* 2014;**13**. doi:10.1186/1476-069X-13-29
- 454 11 Smith AH, Marshall G, Yuan Y, *et al.* Evidence from Chile that arsenic in drinking water  
455 may increase mortality from pulmonary tuberculosis. *Am J Epidemiol* 2011;**173**:414–20.  
456 doi:10.1093/aje/kwq383
- 457 12 Smith AH, Marshall G, Yuan Y, *et al.* Increased mortality from lung cancer and  
458 bronchiectasis in young adults after exposure to arsenic in utero and in early childhood.  
459 *Environ Health Perspect* 2006;**114**:1293–6. doi:10.1289/ehp.8832
- 460 13 Attreed SE, Navas-Acien A, Heaney CD. Arsenic and Immune Response to Infection  
461 During Pregnancy and Early Life. *Cur Environ Health Rep* 2017;**4**:229–43.  
462 doi:10.1007/s40572-017-0141-4
- 463 14 Islam LN, Nabi AHMN, Rahman MM, *et al.* Association of respiratory complications and  
464 elevated serum immunoglobulins with drinking water arsenic toxicity in human. *J Environ*  
465 *Sci Health A Tox Hazard Subst Environ Eng* 2007;**42**:1807–14.  
466 doi:10.1080/10934520701566777
- 467 15 Farzan SF, Korricks S, Li Z, *et al.* In utero arsenic exposure and infant infection in a United  
468 States cohort: a prospective study. *Environ Res* 2013;**126**:24–30.  
469 doi:10.1016/j.envres.2013.05.001
- 470 16 Farzan SF, Li Z, Korricks SA, *et al.* Infant Infections and Respiratory Symptoms in Relation  
471 to in Utero Arsenic Exposure in a U.S. Cohort. *Environ Health Perspect* 2016;**124**:840–7.  
472 doi:10.1289/ehp.1409282
- 473 17 Ahmed SM, Branscum A, Welch BM, *et al.* A prospective cohort study of in utero and early  
474 childhood arsenic exposure and infectious disease in 4- to 5-year-old Bangladeshi children.  
475 *Environ Epidemiol* 2020;**4**:e086. doi:10.1097/EE9.0000000000000086

- 476 18 George CM, Brooks WA, Graziano JH, *et al.* Arsenic exposure is associated with pediatric  
477 pneumonia in rural Bangladesh: a case control study. *Environ Health* 2015;**14**:83.  
478 doi:10.1186/s12940-015-0069-9
- 479 19 Rahman A, Vahter M, Ekström E-C, *et al.* Arsenic exposure in pregnancy increases the  
480 risk of lower respiratory tract infection and diarrhea during infancy in Bangladesh. *Environ*  
481 *Health Perspect* 2011;**119**:719–24. doi:10.1289/ehp.1002265
- 482 20 Raqib R, Ahmed S, Sultana R, *et al.* Effects of in utero arsenic exposure on child immunity  
483 and morbidity in rural Bangladesh. *Toxicol Lett* 2009;**185**:197–202.  
484 doi:10.1016/j.toxlet.2009.01.001
- 485 21 Smith AH, Yunus M, Khan AF, *et al.* Chronic respiratory symptoms in children following in  
486 utero and early life exposure to arsenic in drinking water in Bangladesh. *Int J Epidemiol*  
487 2013;**42**:1077–86. doi:10.1093/ije/dyt120
- 488 22 Kuo CC, Moon KA, Wang SL, *et al.* The association of arsenic metabolism with cancer,  
489 cardiovascular disease, and diabetes: A systematic review of the epidemiological  
490 evidence. *Environ Health Perspect* 2017;**125**. doi:10.1289/EHP577
- 491 23 Hopenhayn C, Huang B, Christian J, *et al.* Profile of urinary arsenic metabolites during  
492 pregnancy. *Environ Health Perspect* 2003;**111**:1888–91. doi:10.1289/ehp.6254
- 493 24 Concha G, Vogler G, Lezcano D, *et al.* Exposure to inorganic arsenic metabolites during  
494 early human development. *Toxicol Sci* 1998;**44**:185–90. doi:10.1006/toxs.1998.2486
- 495 25 World Health Organization. WHO position paper on influenza vaccines - November 2012.  
496 *Weekly Epidemiological Record* 2012;**87**:461–76.
- 497 26 Zaman K, Roy E, Arifeen SE, *et al.* Effectiveness of maternal influenza immunization in  
498 mothers and infants. *New Engl J Med* 2008;**359**:1555–64. doi:10.1056/NEJMoa0708630
- 499 27 Reuman PD, Ayoub EM, Small PA. Effect of passive maternal antibody on influenza illness  
500 in children: a prospective study of influenza A in mother-infant pairs. *Pediatr Infect Dis J*  
501 1987;**6**:398–403. doi:10.1097/00006454-198704000-00011

- 502 28 Puck JM, Glezen WP, Frank AL, *et al.* Protection of infants from infection with influenza A  
503 virus by transplacentally acquired antibody. *J Infect Dis* 1980;**142**:844–9.  
504 doi:10.1093/infdis/142.6.844
- 505 29 Glezen WP, Taber LH, Frank AL, *et al.* Influenza virus infections in infants. *Pediatr Infect*  
506 *Dis J* 1997;**16**:1065–8. doi:10.1097/00006454-199711000-00012
- 507 30 Neuzil KM, Reed GW, Mitchel EF, *et al.* Impact of influenza on acute cardiopulmonary  
508 hospitalizations in pregnant women. *Am J Epidemiol* 1998;**148**:1094–102.  
509 doi:10.1093/oxfordjournals.aje.a009587
- 510 31 Ser PH, Banu B, Jebunnesa F, *et al.* Arsenic exposure increases maternal but not cord  
511 serum IgG in Bangladesh. *Pediatr Int* 2015;**57**:119–25. doi:10.1111/ped.12396
- 512 32 Attreed SE, Navas-Acien A, Heaney CD. Arsenic and Immune Response to Infection  
513 During Pregnancy and Early Life. *Curr Environ Health Rep* 2017;**4**:229–43.  
514 doi:10.1007/s40572-017-0141-4
- 515 33 Flanagan S v, Johnston RB, Zheng Y. Arsenic in tube well water in Bangladesh: health and  
516 economic impacts and implications for arsenic mitigation. *Bull World Health Organ*  
517 2012;**90**:839–46. doi:10.2471/BLT.11.101253
- 518 34 Ali H, Hamadani J, Mehra S, *et al.* Effect of maternal antenatal and newborn  
519 supplementation with Vitamin A on cognitive development of school-aged children in rural  
520 Bangladesh: A follow-up of a placebo-controlled, randomized trial. *Am J Clin Nutr*  
521 2017;**106**:77–87. doi:10.3945/ajcn.116.134478
- 522 35 Klemm RDW, Labrique AB, Christian P, *et al.* Newborn Vitamin A Supplementation  
523 Reduced Infant Mortality in Rural Bangladesh. *Pediatrics* 2008;**122**:e242–50.  
524 doi:10.1542/peds.2007-3448
- 525 36 West Jr. KP, Christian P, Labrique AB, *et al.* Effects of vitamin A or beta carotene  
526 supplementation on pregnancy-related mortality and infant mortality in rural Bangladesh: A  
527 cluster randomized trial. *JAMA* 2011;**305**:1986–95. doi:10.1001/jama.2011.656


- 528 37 West Jr. KP, Shamim AA, Mehra S, *et al.* Effect of Maternal Multiple Micronutrient vs Iron-  
529 Folic Acid Supplementation on Infant Mortality and Adverse Birth Outcomes in Rural  
530 Bangladesh: The Jivita-3 Randomized Trial. *JAMA* 2014;**312**:2649–58.  
531 doi:10.1001/jama.2014.16819
- 532 38 Serradell L, Wagué S, Moureau A, *et al.* Enhanced passive safety surveillance of a trivalent  
533 and a quadrivalent influenza vaccine in Denmark and Finland during the 2018/2019  
534 season. *Hum Vaccin Immunother* 2021;**17**:1205–10.  
535 doi:10.1080/21645515.2020.1804247
- 536 39 Gunnsteinsson S, Labrique AB, West KP, *et al.* Constructing indices of rural living  
537 standards in Northwestern Bangladesh. *J Health Popul Nutr* 2010;**28**:509–19.  
538 doi:10.3329/jhpn.v28i5.6160
- 539 40 Cheng Z, Zheng Y, Mortlock R, *et al.* Rapid multi-element analysis of groundwater by high-  
540 resolution inductively coupled plasma mass spectrometry. *Anal Bioanal Chem*  
541 2004;**379**:512–8. doi:10.1007/s00216-004-2618-x
- 542 41 Weinberg A. Cryopreservation of Peripheral Blood Mononuclear Cells. In: Detrick B,  
543 Schmitz JL, Hamilton RG, eds. *Manual of Molecular and Clinical Laboratory Immunology*.  
544 Washington, DC: ASM Press 2016. 263–8.
- 545 42 Ohmit SE, Petrie JG, Cross RT, *et al.* Influenza hemagglutination-inhibition antibody titer  
546 as a correlate of vaccine-induced protection. *J Infect Dis* 2011;**204**:1879–85.  
547 doi:10.1093/infdis/jir661
- 548 43 Scheer J, Findenig S, Goessler W, *et al.* Arsenic species and selected metals in human  
549 urine: validation of HPLC/ICPMS and ICPMS procedures for a long-term population-based  
550 epidemiological study. *Anal Methods* 2012;**4**:406–13. doi:10.1039/C2AY05638K
- 551 44 National Research Council. *Arsenic in Drinking Water*. Washington, DC: : National  
552 Academies Press 1999. doi:10.17226/6444

- 553 45 McKie A, Vyse A, Maple C. Novel methods for the detection of microbial antibodies in oral  
554 fluid. *Lancet Infect Dis* 2002;**2**:18–24. doi:10.1016/s1473-3099(01)00169-4
- 555 46 Randad PR, Hayford K, Baldwin R, *et al.* The Utility of Antibodies in Saliva to Measure  
556 Pathogen Exposure and Infection. In: Granger Douglas A., Taylor Marcus K., eds. *Salivary*  
557 *Bioscience: Foundations of Interdisciplinary Saliva Research and Applications*. Cham,  
558 Switzerland: Springer Nature 2020. 287–319. doi:10.1007/978-3-030-35784-9
- 559 47 Brandtzaeg PER. Do salivary antibodies reliably reflect both mucosal and systemic  
560 immunity? *Ann N Y Acad Sci* 2007;**1098**:288–311. doi:10.1196/annals.1384.012
- 561 48 Randad PR, Pisanic N, Kruczynski K, *et al.* COVID-19 serology at population scale: SARS-  
562 CoV-2-specific antibody responses in saliva. *J Clin Microbiol* 2020;**59**:e02204.  
563 doi:10.1128/JCM.02204-20
- 564 49 Fitzner J, Qasmieh S, Mounts AW, *et al.* Revision of clinical case definitions: influenza-like  
565 illness and severe acute respiratory infection. *Bull World Health Organ* 2018;**96**:122–8.  
566 doi:10.2471/BLT.17.194514
- 567 50 World Health Organization (WHO). Information for the Molecular Detection of Influenza  
568 Viruses.  
569 2017.[https://www.who.int/influenza/gisrs\\_laboratory/WHO\\_information\\_for\\_the\\_molecular](https://www.who.int/influenza/gisrs_laboratory/WHO_information_for_the_molecular_detection_of_influenza_viruses_20171023_Final.pdf)  
570 [\\_detection\\_of\\_influenza\\_viruses\\_20171023\\_Final.pdf](https://www.who.int/influenza/gisrs_laboratory/WHO_information_for_the_molecular_detection_of_influenza_viruses_20171023_Final.pdf)
- 571 51 West Jr. KP, Shamim AA, Labrique AB, *et al.* Efficacy of Antenatal Multiple Micronutrient  
572 (MM) vs Iron-Folic Acid (IFA) Supplementation in Improving Gestational and Postnatal  
573 Viability in Rural Bangladesh: The JiVitA-3 Trial. *FASEB J* 2013;**27**:358.6-358.6.  
574 doi:10.1096/fasebj.27.1\_supplement.358.6
- 575 52 Kim JM, Labrique A, West KP, *et al.* Maternal morbidity in early pregnancy in rural northern  
576 Bangladesh. *Int J Gynaecol Obstet* 2012;**119**:227–33. doi:10.1016/j.ijgo.2012.06.022

- 577 53 World Health Organization (WHO). Haemoglobin concentrations for the diagnosis of  
578 anaemia and assessment of severity. Geneva, Switzerland: 2011.  
579 <https://www.who.int/vmnis/indicators/haemoglobin.pdf>
- 580 54 Ahsan H, Chen Y, Parvez F, *et al.* Health Effects of Arsenic Longitudinal Study (HEALS):  
581 description of a multidisciplinary epidemiologic investigation. *J Expo Sci Environ Epidemiol*  
582 2006;**16**:191–205. doi:10.1038/sj.jea.7500449
- 583 55 Rahman A, Vahter M, Ekström E-C, *et al.* Association of arsenic exposure during  
584 pregnancy with fetal loss and infant death: a cohort study in Bangladesh. *Am J Epidemiol*  
585 2007;**165**:1389–96. doi:10.1093/aje/kwm025
- 586 56 Navas-Acien A, Francesconi KA, Silbergeld EK, *et al.* Seafood intake and urine  
587 concentrations of total arsenic, dimethylarsinate and arsenobetaine in the US population.  
588 *Environmental Research* 2011;**111**:110–8. doi:10.1016/j.envres.2010.10.009
- 589 57 Huhmann LB, Harvey CF, Navas-Acien A, *et al.* A mass-balance model to assess arsenic  
590 exposure from multiple wells in Bangladesh. *J Expo Sci Environ Epidemiol* 2021;:1–9.  
591 doi:10.1038/s41370-021-00387-5
- 592 58 Semmes EC, Chen J-L, Goswami R, *et al.* Understanding early-life adaptive immunity to  
593 guide interventions for pediatric health. *Frontiers in Immunology* 2021;**11**:3544.  
594 doi:10.3389/fimmu.2020.595297
- 595  
596


597 **TABLES AND FIGURES**

598 **Figure 1.** Map of the Pregnancy, Arsenic, and Immune Response (PAIR) Study area within the  
599 Jivita Maternal and Child Health and Nutrition Research Project in northern Bangladesh,  
600 indicating the original study area (dark gray), extensions to the study area to achieve the target  
601 sample size in the same influenza season and before the Ramadan fast (light gray), and  
602 remaining Jivita area (white). Sector boundaries are represented by light gray lines. Clinical  
603 centers where biospecimen collection was performed are noted by black circles. Major roads are  
604 indicated by black lines. The inset indicates the approximate location of the PAIR Study (black  
605 square) in Bangladesh.






607 **Figure 2.** Eligibility and enrollment in the Pregnancy, Arsenic, and Immune Response (PAIR)  
608 Study, Gaibandha District, Bangladesh, 2018-2019. We conducted pregnancy surveillance from  
609 July 2018 to February 2019 and enrolled eligible pregnant women from October 2018 to March  
610 2019. \*Initially, pregnant women were eligible at 13-14 weeks of gestational age (GW). In  
611 November 2018, we expanded eligibility to 13-16 GW.



612




613 **Figure 3.** Tube well water arsenic (wAs) and urinary inorganic, monomethyl (MMA), and dimethyl  
614 (DMA) arsenic, and their sum ( $\Sigma$ uAs), plotted on a common log scale, among pregnant women  
615 at enrollment in the Pregnancy, Arsenic, and Immune Response (PAIR) Study, Gaibandha  
616 District, Bangladesh, 2018-2019.



617

618 **Figure 4.** Tube well water arsenic (wAs) and the sum of urinary inorganic, monomethyl, and  
619 dimethyl arsenic ( $\Sigma$ uAs), plotted on a common log scale, among pregnant women at enrollment  
620 in the Pregnancy, Arsenic, and Immune Response (PAIR) Study, Gaibandha District, Bangladesh,  
621 2018-2019. A generalized additive model smoother is shown by the solid line. Drinking water  
622 arsenic standards for the World Health Organization (10  $\mu$ g/L) and Bangladesh (50  $\mu$ g/L) are  
623 indicated by dashed vertical lines.



624